Pamela is a European and UK Patent Attorney with 20 years’ professional experience. Much of her day-to-day practice involves prosecuting patent applications at the European Patent Office (EPO) and coordinating the prosecution of worldwide patent portfolios. She has substantial experience of oppositions and appeals at the EPO including, in particular, multi-party oppositions on antibody cases. Pamela has also been involved in UK patent litigation, notably in the UK court case GSK v Genentech  FSR 18 relating to antibodies for treating rheumatoid arthritis, and in a successful ownership dispute over a Chinese patent in the Chinese courts.
She handles European patent applications across a range of biotechnology and life sciences subject matter, including antibodies and their uses, viral vectors, peptide vaccines, antisense nucleic acids, stem cells and biomarkers.
Pamela’s client base includes large pharmaceutical companies, biotechnology companies and academic institutions, located in the UK, US, Japan and elsewhere. She also handles European and foreign applications for start-up companies developing technologies which include synthetic viral vaccines and immunological assays. Notably, she acted for BioVex Limited, which developed a modified herpes simplex virus effective in treating cancer, handling its patent portfolio and several EPO oppositions, prior to its high-value acquisition by Amgen.
Pamela joined J A Kemp in 1999 and became a partner in 2008.